82 related articles for article (PubMed ID: 16028404)
21. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
23. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma.
Raspollini MR; Castiglione F; Garbini F; Villanucci A; Amunni G; Baroni G; Boddi V; Taddei GL
Int J Surg Pathol; 2005 Apr; 13(2):135-42. PubMed ID: 15864375
[TBL] [Abstract][Full Text] [Related]
24. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.
Gilmour LM; Macleod KG; McCaig A; Gullick WJ; Smyth JF; Langdon SP
Cancer Res; 2001 Mar; 61(5):2169-76. PubMed ID: 11280782
[TBL] [Abstract][Full Text] [Related]
25. [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
Chen AP; Zhang J; Liu H; Zhao SP; Dai SZ; Sun XL
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):48-52. PubMed ID: 19538870
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours.
Higgins PA; Brady A; Dobbs SP; Salto-Tellez M; Maxwell P; McCluggage WG
Histopathology; 2014 Apr; 64(5):633-8. PubMed ID: 24206174
[TBL] [Abstract][Full Text] [Related]
28. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters.
Scambia G; Ferrandina G; Marone M; Benedetti Panici P; Giannitelli C; Piantelli M; Leone A; Mancuso S
J Clin Oncol; 1996 Feb; 14(2):334-42. PubMed ID: 8636741
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
30. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
[TBL] [Abstract][Full Text] [Related]
31. The status of epidermal growth factor receptor in borderline ovarian tumours.
Showeil R; Romano C; Valganon M; Lambros M; Trivedi P; Van Noorden S; Sriraksa R; El-Kaffash D; El-Etreby N; Natrajan R; Foroni L; Osborne R; El-Bahrawy M
Oncotarget; 2016 Mar; 7(9):10568-77. PubMed ID: 26870997
[TBL] [Abstract][Full Text] [Related]
32. Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer.
Ljuslinder I; Melin B; Henriksson ML; Öberg Å; Palmqvist R
Int J Cancer; 2011 May; 128(9):2031-7. PubMed ID: 20635387
[TBL] [Abstract][Full Text] [Related]
33. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Olsen DA; Corydon T; Lorentzen KA; Knudsen HJ; Jeppesen U; Brandslund I; Jakobsen A
Clin Cancer Res; 2008 Jun; 14(11):3278-82. PubMed ID: 18519753
[TBL] [Abstract][Full Text] [Related]
34. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.
Cîrstea AE; Stepan AE; Mărgăritescu C; Zăvoi RE; Olimid DA; Simionescu CE
Rom J Morphol Embryol; 2017; 58(4):1269-1273. PubMed ID: 29556616
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Tropé CG; Nesland JM; Holm R
Anticancer Res; 1999; 19(5C):4469-74. PubMed ID: 10650794
[TBL] [Abstract][Full Text] [Related]
36. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
39. E-Cadherin complex protein expression and survival in ovarian carcinoma.
Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
[TBL] [Abstract][Full Text] [Related]
40. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas.
Porebska I; Harlozińska A; Bojarowski T
Tumour Biol; 2000; 21(2):105-15. PubMed ID: 10686540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
